CLINICAL_TRIALS
trial_result
· 2016-02-11
Clinical Trial Update: Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer [Phase 2]
Summary
A Phase 2 trial of afatinib (BIBW2992) in HER2-overexpressing inflammatory breast cancer has completed, with results posted in 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2016-02-11